6-Substituted 3,4-Dihydro-naphthalene-2-carboxylic Acids: Synthesis and Structure-Activity Studies in a Novel Class of Human 5 Reductase Inhibitors

• Published in: Journal of enzyme inhibition and medicinal chemistry Vol. 17; no. 5; pp. 303 - 320
• Main Authors: Baston, Eckhard, Salem, Ola I.A., Hartmann, Rolf W.
• Format: Journal Article
• Language: English
• Published: Informa UK Ltd 2002
• ISSN: 1475-6366; 1475-6374
• DOI: 10.1080/1475636021000059092

Novel 3,4-dihydro-naphthalene-2-carboxylic acids were synthesized and evaluated for 5 α reductase inhibitory activity. This enzyme exists in two isoforms and is a pharmacological target for the treatment of benign prostatic hyperplasia, male pattern baldness and acne. In the present study non-steroidal compounds capable of mimicking the transition state of the steroidal substrates were prepared. The synthetic strategy for the preparation of compounds 1 - 6 consisted of triflation followed by subsequent Heck-type carboxylation or methoxy carbonylation for 6-phenyl-3,4-dihydro-naphthalen-2(1H)-one 1c. A Negishi-type coupling reaction between 6-(trifluoro-methanesulfonyloxy)-3,4-dihydro-naphthalene-2-carboxylic acid methyl ester 7b and various aryl bromides led, after further transformations, to 6-substituted 3,4-dihydro-naphthalene-2-carboxylic acids 7 - 15. In a similar way the corresponding naphthalene-2-carboxylic acids 16 and 17 were obtained. The DU 145 cell line and prostate homogenates served as enzyme sources for the human type 1 and type 2 isozymes, whereas ventral prostate was employed to evaluate rat isozyme inhibitory potency. The most active inhibitors identified in this study were 6-[4- (N, N -dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid (3) (IC 50 =0.09 μM, rat type 1), 6-[3- (N, N -dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid (13) (IC 50 =0.75 μM, human type 2; IC 50 =0.81 μM, human type 1) and 6-[4- (N, N -diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid (16) (IC 50 =0.2 μM, human type 2). The latter compound was shown to deactivate the enzyme in an uncompetitive manner (Ki=90 nM; Km, Testosterone=0.8-1.0 μM) similar to the steroidal inhibitor Epristeride. Select inhibitors (13 and 16) were tested in vivo using testosterone propionate-treated, juvenile, orchiectomized SD-rats. None of the compounds was active at a dose of 25 mg/kg. This result might in part be ascribed to the relatively poor in vitro rat isozyme inhibitory potency.